Keith Bentley
About Keith Bentley
Keith Bentley is an Associate Principal Scientist at LifeMine Therapeutics, specializing in the development of antibody-drug conjugates for cancer treatment. He holds a Bachelor's degree in Biochemistry from The University of Alabama and a Ph.D. in Organic Chemistry from Georgetown University.
Work at LifeMine Therapeutics
Keith Bentley serves as an Associate Principal Scientist at LifeMine Therapeutics, a position he has held since 2021. Located in Cambridge, Massachusetts, he is involved in advancing the company's mission to develop innovative therapies. His role focuses on leveraging his expertise in antibody-drug conjugates (ADCs) to contribute to the development of novel treatments for cancer patients.
Education and Expertise
Keith Bentley holds a Bachelor’s Degree in Biochemistry from The University of Alabama, where he studied from 2005 to 2009. He furthered his education at Georgetown University, earning a Doctor of Philosophy (Ph.D.) in Organic Chemistry from 2010 to 2015. He completed a Postdoctoral Fellowship in Organic Methodology at the Massachusetts Institute of Technology (MIT) from 2015 to 2017. His expertise lies in developing first and best-in-class ADCs for cancer treatment.
Background
Keith Bentley has a solid academic and professional background in biochemistry and organic chemistry. He began his academic journey at The University of Alabama, followed by advanced studies at Georgetown University and MIT. His professional experience includes significant roles at Mersana Therapeutics and MIT, where he contributed to various research projects and collaborations.
Previous Experience at Mersana Therapeutics
Prior to his current role, Keith Bentley worked at Mersana Therapeutics as a Senior Scientist from 2017 to 2021. During his tenure, he contributed to multiple discovery projects in a highly collaborative environment, focusing on the development of innovative therapies for cancer treatment.
Postdoctoral Fellowship at MIT
Keith Bentley completed a Postdoctoral Fellowship at the Massachusetts Institute of Technology (MIT) in the Van Humbeck Group from 2015 to 2017. This experience allowed him to deepen his research skills and knowledge in organic methodology, further preparing him for his future roles in the biotechnology sector.